Multiple clinical data readouts expected in second half of 2022
LOS GATOS, Calif., Aug. 16, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its second quarter ended June 30, 2022.
Read more at prnewswire.com